DUSA Pharmaceuticals awarded preliminary injunctive relief prohibiting Biofrontera from using trade secrets

DUSA Pharmaceuticals Inc., the wholly owned subsidiary of Sun Pharmaceutical Industries announced that DUSA has been granted preliminary injunctive relief by a federal district court prohibiting defendants Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (together known as Biofrontera) from using DUSA's confidential and proprietary trade secret information.

DUSA had filed a lawsuit against the Biofrontera defendants earlier this year in the US District Court for the District of Massachusetts. The lawsuit alleges trade secret misappropriation and patent infringement of DUSA's photodynamic therapy (PDT) patents, US 9,723,991 and US 8,216,289, covering DUSA's product, LEVULAN KERASTICK (aminolevulinic acid HCl) for topical solution, 20% used with DUSA's BLU-U Blue Light Photodynamic Therapy Illuminator.

Powered by Capital Market - Live News